Efavirenz and Lopinavir/Ritonavir Alter Cell Cycle Regulation in Lung Cancer.
cell cycle
cell death
cell proliferation
efavirenz
lopinavir/ritonavir
lung cancer
real-time cell analysis
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2020
2020
Historique:
received:
03
04
2020
accepted:
29
07
2020
entrez:
28
9
2020
pubmed:
29
9
2020
medline:
29
9
2020
Statut:
epublish
Résumé
Highly active anti-retroviral treatment (HAART) is currently the most effective treatment for HIV/AIDS. Additionally, HIV positive patients receiving HAART have a better health-related quality of life (HRQoL). Cancers previously associated with HIV/AIDS also known as the AIDS defining cancers (ADCs), such as Kaposi's sarcoma and non-Hodgkin's lymphoma have been on the decline since the introduction of HAART. However, non-AIDS defining cancers (NADCs), in particular, lung cancers have been documented to be on the rise. The association between the use of HAART components and lung carcinogenesis is poorly understood. This study aimed at elucidating the effects of two HAART components [efavirenz (EFV), and lopinavir/ritonavir (LPV/r)] on lung cancer. This was achieved through the use of
Identifiants
pubmed: 32984047
doi: 10.3389/fonc.2020.01693
pmc: PMC7484481
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1693Informations de copyright
Copyright © 2020 Marima, Hull, Dlamini and Penny.
Références
Cell. 2012 Sep 14;150(6):1121-34
pubmed: 22980976
Oncol Res Treat. 2017;40(3):88-92
pubmed: 28259887
Leuk Res. 2014 Mar;38(3):383-92
pubmed: 24418752
PLoS One. 2012;7(9):e44793
pubmed: 23028623
Int J Cancer. 2017 Apr 15;140(8):1713-1726
pubmed: 27870005
Expert Opin Pharmacother. 2008 Sep;9(13):2363-75
pubmed: 18710360
AIDS Rev. 2013 Jan-Mar;15(1):38-48
pubmed: 23449228
Mol Cancer. 2009 Apr 22;8:26
pubmed: 19386116
J Immunol Methods. 1998 Apr 15;213(2):157-67
pubmed: 9692848
Free Radic Biol Med. 2013 Dec;65:778-788
pubmed: 23973637
Cell Transplant. 2016 Nov;25(11):1967-1977
pubmed: 28836850
Int J STD AIDS. 2011 Jan;22(1):11-4
pubmed: 21364060
AIDS. 2013 Aug 24;27(13):2031-40
pubmed: 23612009
Cell Physiol Biochem. 2015;37(6):2486-95
pubmed: 26681533
Curr HIV Res. 2012 Oct;10(7):597-605
pubmed: 22716104
Drugs. 2010 Oct 1;70(14):1885-915
pubmed: 20836579
Nature. 2008 Oct 23;455(7216):1069-75
pubmed: 18948947
J Microsc Ultrastruct. 2017 Jan-Mar;5(1):39-48
pubmed: 30023236
S Afr Med J. 2011 May;101(5):321
pubmed: 21837873
AIDS Res Ther. 2018 Oct 27;15(1):16
pubmed: 30368240
Carcinogenesis. 2012 Jul;33(7):1270-6
pubmed: 22510280
AIDS Res Hum Retroviruses. 2014 May;30(5):425-33
pubmed: 24380397
AIDS. 2014 Feb 20;28(4):453-65
pubmed: 24401642
Clin Chest Med. 2011 Dec;32(4):703-40
pubmed: 22054881
Top Antivir Med. 2014 Jun-Jul;22(3):660-5
pubmed: 25101532
J Thorac Oncol. 2011 Feb;6(2):343-50
pubmed: 21173714
Infect Dis (Lond). 2020 May;52(5):295-329
pubmed: 31928282
Ann Intern Med. 2010 Oct 5;153(7):452-60
pubmed: 20921544
J Neurooncol. 2011 Feb;101(3):441-8
pubmed: 20596751
Cancer Lett. 2014 Jan 1;342(1):52-9
pubmed: 24012878
Curr Opin HIV AIDS. 2017 Jan;12(1):12-19
pubmed: 27755153
Oncol Lett. 2018 Feb;15(2):1728-1736
pubmed: 29434868
BMC Infect Dis. 2019 Sep 5;19(1):775
pubmed: 31488063
Anticancer Res. 2019 Nov;39(11):5891-5901
pubmed: 31704813
Invest New Drugs. 2019 Oct;37(5):1014-1028
pubmed: 30706336
S Afr Med J. 2016 Jun 17;106(7):666-8
pubmed: 27384354
J Thorac Dis. 2013 Oct;5 Suppl 5:S479-90
pubmed: 24163741
J Antimicrob Chemother. 2015 Feb;70(2):543-9
pubmed: 25281400